Omega-3 fatty acids moderate effects of physical activity on cognitive function

Regina L. Leckie, Stephen B. Manuck, Neha Bhattacharjee, Matthew F. Muldoon, Janine M. Flory, Kirk I. Erickson

1. Introduction

Several modifiable behaviors influence cognitive performance throughout the lifespan. For example, physical activity (PA) is a modifiable behavior that influences brain and cognitive health. In children and adolescents, greater engagement in PA is associated with elevated cognitive performance and higher academic achievement scores (Castelli et al., 2007; Hillman et al., 2009). During mid-life, PA is associated with improved cognitive performance on tasks of memory, processing speed, and executive function (Etter et al., 2006; Singh-Manoux et al., 2005). Furthermore, prospective and retrospective epidemiological studies suggest that PA during mid-life is predictive of cognitive outcomes in old age, and that increasing PA earlier in life may prevent or delay future cognitive impairment (Middleton et al., 2010; Rovio et al., 2005). Yet, beginning a physically active lifestyle in late adulthood is not futile; even modest amounts of PA in late life is sufficient for improving cognitive performance (Colcombe & Kramer, 2003).

Improvements in cognitive function translate to PA-induced changes in brain morphology and function. For example, randomized controlled trials of PA suggest that it increases hippocampal (Erickson et al., 2011) and prefrontal cortex (Colcombe et al., 2006) volume, as well as functional connectivity of hippocampal and prefrontal regions (Voss et al., 2010), and increases task-evoked brain activity (Colcombe et al., 2004; Prakash et al., 2011). Cross-sectional studies of PA and physical fitness find similar patterns, suggesting a consistent effect on cognitive health in multiple populations and with multiple experimental designs.

In addition to the favorable effects of PA on cognitive function, other modifiable lifestyle factors may also contribute to cognitive function throughout the lifespan. For example, greater intake of long-chain, omega-3 polyunsaturated fatty acids (PUFA) was associated with better working memory, processing speed and...
cognitive flexibility in a sample of middle-aged adults (Kalmijn et al., 2004). In particular, higher exposure to docosahexaenoic acid (DHA), an omega-3 PUFA that is highly concentrated in the brain, has been associated with better performance on measures of executive function (Dullemeneger et al., 2007; Kalmijn et al., 2004). In line with this evidence, neuroimaging studies have reported that greater levels of omega-3 PUFAs are related to fewer white matter hyperintensities and greater corticolumbic gray matter volume (Conklin et al., 2007; Tan et al., 2012). Nonetheless, the effects of the omega-3 PUFA DHA on neurocognitive function appear to be less conclusive than the effects of PA.

In fact, several studies report little benefit of omega-3 intake on cognitive function (de Lorgeril et al., 1994; Pistell et al., 2010; Oksman et al., 2006), and initial randomized trials directly testing the effects of raised omega-3 intake have yielded only limited evidence of improved cognitive performance (Antypa et al., 2009; Chiu et al., 2008; Dangour et al., 2010; Fontani et al., 2005; Freund-Levi et al., 2006; Giltay et al., 2012; Rogers et al., 2008; Stonehouse et al., 2013; van de Rest et al., 2008). Some studies (Antypa et al., 2009; Bourre, 2004; Fontani et al., 2005; Gomez-Pinilla, 2008) suggest that associations between omega-3 and cognitive performance may be domain specific with some cognitive functions (i.e., executive functions) being more sensitive to omega-3 than others. However, other studies have been more equivocal with respect to the cognitive domains affected in younger and mid-life adults. For example, a six-month DHA supplementation in healthy adults aged 18–45 years found improvements in response time for working memory tasks in men, but episodic memory tasks in women (Stonehouse et al., 2013). Furthermore, a 12-week DHA supplementation with healthy adults aged 18–35 years reported no significant improvements on any of the 15 neuropsychological tests administered (Jackson et al., 2012). It is possible that some of this heterogeneity may be explained by interactions between PUFAs and other lifestyle variables, such as PA.

On the molecular level, omega-3 and PA share some similar effects. For example, in rodents DHA supplementation rescues the effect of a DHA deficient diet on D2 receptors in the striatum (Davis et al., 2010) and loss of dopaminergic cells in the substantia nigra in models of Parkinson’s Disease (Bousquet et al., 2008). Likewise, rodent models demonstrate that PA affects dopaminergic function in reward pathways (Pothakos, Kurz, & Lau, 2009; Ridgell, Vitek, & Alberts, 2009; Speelman et al., 2011) and rescues dopamine depletion in hemi-parkinsonian models (Petzinger et al., 2007; Pothakos et al., 2009). Human studies of Parkinson’s disease also show increased dopamine production and release (Ouchi et al., 2001) and cognitive and motor improvements with increased PA (Ridgell et al., 2009). In addition to dopamine, both DHA supplementation and PA influence the expression of brain-derived neurotrophic factor (BDNF), which promotes synaptic plasticity, cell proliferation and cell survival in humans (Erickson et al., 2011) and rodents (Wu, Ying, & Gomez-Pinilla, 2008). Furthermore, both DHA (Kadoglou et al., 2011; Nichol et al., 2008; Parachikova, Nichol, & Gotman, 2008; Yue et al., 2009) and PA (Fotuhi, Mohassel, & Yaffe, 2009; Oksman et al., 2006) have been associated with reduced β-amyloid (Aβ) plaque deposits, a putative cause of cognitive impairment and Alzheimer’s Disease (AD). Finally, both PA and DHA may regulate the expression of inflammatory cytokines (Kiecotto-Claser et al., 2012; Rana et al., 2011; Rangel-Huerta et al., 2012); higher levels of which have been closely linked to a reduction in gray matter volume (Kopf, Bachmann, & Marsland, 2010; Marsland et al., 2008) and impaired executive function (Wersching et al., 2010) and memory (Bettcher et al., 2012) in humans.

Relative to the role of PUFAs in the inflammatory response, there is debate over the most appropriate method of quantifying arachidonic acid (AA; pro-inflammatory) and DHA (anti-inflammatory) levels in humans (Klingler & Koletzko, 2012). Since these n-6 and n-3 PUFAs are precursors of relatively pro- and anti-inflammatory eicosanoids, respectively (Wallis, Watts, & Browse, 2002), the n-6:n-3 ratio has been recommended as an index of DHA effectiveness. High ratios, reflecting a high proportion of AA to DHA, are associated with diminished physical health outcomes and increased incidence of inflammatory diseases (Hu, Manson, & Willett, 2001). Conversely, a low ratio has been associated with better cardiovascular and cognitive health (Dullemeneger et al., 2007; de Lorgeril et al., 1994).

Because of the shared neurobiological and physiological effects of PA and DHA intake, several human and animal studies have speculated about the additive or multiplicative benefits that might arise from combining omega-3 supplementation with PA (Gómez-Pinilla & Feng, 2012). For example, PA may provide an avenue by which the effects of DHA on cellular integrity and cognitive function are enhanced (Gómez-Pinilla & Feng, 2012; Wu et al., 2008). In rodents, the combination of PA and DHA supplementation (1.25% increase of DHA in standard rat chow) have additive effects on synaptic plasticity and membrane structure biomarkers in the dentate gyrus of the hippocampus, such that mice receiving both DHA supplementation and PA have greater levels of synaptic proteins than their counterparts not receiving PA (Chytrova, Ying, & Gomez-Pinilla, 2010). However, these effects were not mirrored behaviorally. Instead, physical inactivity without DHA supplementation resulted in impaired learning compared to mice with DHA supplementation, PA, or both (Chytrova et al., 2010). Studies in humans have not yet examined whether DHA levels moderate the effect of PA on cognitive performance in a similar way to that demonstrated in rodents.

The present study examined whether DHA omega-3 fatty acid levels moderate the effect of PA on executive function and working memory in humans. This report is an extension of our prior report on omega-3 fatty acids and cognitive performance (Muldoon et al., 2010), now containing an expanded sample with a focus on DHA through the AA:DHA ratio, as well as additional cognitive outcome variables and dietary covariates. We expected effects to be specific to executive function and working memory domains because these areas have been shown to be sensitive to both PA (Smith et al., 2010) and omega-3 exposure (Kalmijn et al., 2004; Muldoon et al., 2010) in prior studies. We reasoned that DHA omega-3 levels might moderate effects of PA in several ways. First, greater amounts of DHA might potentiate the effects of higher levels of PA on cognitive function. Such a finding would suggest that combining a diet high in omega-3 with a physically active lifestyle might prove more beneficial to cognitive function than either treatment by itself. However, an alternative outcome is that a deficiency in both PA and omega-3 PUFAs would result in reduced cognitive function. Such a finding might suggest that greater amounts of either omega-3 or PA could be sufficient for elevating cognitive function and that greater amounts of omega-3 could mitigate the deleterious effects of low amounts of PA.

2. Methods

2.1. Participants

Participants were middle-aged adults (30–54 years of age) recruited through the University of Pittsburgh Adult Health and Behavior (AHAB) project (Muldoon et al., 2010). A total of 1379 participants were recruited via mass mail solicitation from communities of southwest Pennsylvania. Exclusion criteria for the AHAB project included a reported history of atherosclerotic cardiovascular disease, chronic kidney or liver disease, cancer treatment in the preceding year, major neurological disorders, schizophrenia or other psychotic illness, and current pregnancy or perimenopausal menstrual irregularities. Participants were required to speak English as their primary language for at least the past 5 years. From the AHAB registry cohort of 1379 individuals, 1295 were included in the AHAB study, where subsets of participants could elect to participate in one or more additional and smaller sub-studies that included, among other measures, blood samples for fatty acids.
acids, and dietary interviews if they met the following additional criteria: (a) resting $BP$ was $<180/110$ mm Hg; (b) body mass index (weight/height$^2$) was $<40$ kg/m$^2$; (c) mean daily alcohol consumption was $\leq$ 21 drinks per week (ethanol $< 273$ g/week); (d) not currently taking any antihypertensive, diabetogenic, lipid-lowering, or any other medications known to affect cognition or psychiatric medications. A total of 383 participants met these additional criteria and agreed to participate. From this sample, we excluded 25 because of various technical difficulties in fatty acid assays, 4 from incomplete cognitive data, 5 because of an IQ < 80, and 5 because they reported taking omega-3 supplements at the time of blood draw. Our final sample size for this study after these exclusions was 344. The study protocol was approved by the Institutional Review Board of the University of Pittsburgh (IRB numbers 0805006, 000355), and informed consent was obtained from all participants in accordance with the University IRB guidelines.

2.2. Measures

Participants completed multiple questionnaires assessing psychosocial, lifestyle and demographic information in addition to completing a physical exam.

2.2.1. Plasma fatty acid serum acquisition

A morning blood sample was obtained after an overnight fast. Following centrifugation, serum samples were stored at 28°C until analysis. Serum phospholipid fatty acid composition was determined by capillary GC as described elsewhere (Yao, Leonard, and Reddy, 2000). DHA and AA levels were expressed as percentages of the total fatty acid pool (weight or mol%). Intra- and interassay coefficients of variation were 2.0–9.2% and 1.9–9.6%, respectively, for all major serum fatty acids and polyunsaturated fatty acids (Muldooon et al., 2010). Our primary analyses were conducted using the AA/DHA ratio since it has been the recommended approach in other studies (Pearl et al., 2011; Hubel et al., 2009; Stonehouse et al., 2013), however, for exploration in additional analyses, we examined the predictive value of DHA and AA individually.

2.2.2. Cognitive measures

A comprehensive battery of cognitive tests was administered to the participants in AHAB including the Wechsler Memory Scale, 3rd edition (WMS-III). From this cognitive battery we selected Trails A and B, spatial and letter n-back tasks, and Logical Memory from the WMS as tasks of interest (see below) because of a priori hypotheses that these cognitive tasks, and the domains that they measure, would be sensitive to both PA and DHA (Gomez-Pinilla, 2011), and therefore likely to show a DHA x PA interaction.

2.2.2.1. N-back task

This task was comprised of two parts, the letter n-back and the spatial n-back. In the letter n-back, participants viewed a series of letters presented sequentially for 500 ms each with an intertrial interval of 2000 ms. In the 1-back condition participants were asked to press a button if the letter currently displayed on the screen matched the letter previously displayed. If the letter did not match the previously presented letter, they were instructed to press a different button. In the 3-back condition participants were asked to determine if the letter currently displayed on the screen matched the letter that was displayed 3 letters prior. There were 56 trials presented (50% match, 50% non-match) for both 1-back and 3-back tasks. The outcome variable of interest was the number of correct responses for each task.

The spatial n-back task was similar to the letter n-back task except that spatial locations, rather than letters, were to be remembered. The participants viewed dots, presented sequentially, on the computer screen for 500 ms each with an intertrial interval of 2000 ms. Participants were instructed to respond when the dot appeared in the same location previously displayed (1-back) or in the same location as two trials before (2-back). Again, there were 56 trials per condition (50% match, 50% non-match). The number of correct responses was recorded and used as the outcome of interest.

2.2.2.2. The Trail Making test

This test measures processing speed (Trails A) and executive function, or task-switching (Trails B). In Trails A, participants were instructed to connect numbers 1–26 in numerical order as quickly as possible without lifting their pencil from the page. In Trails B, participants were instructed to alternate between connecting numbers and letters. Specifically, they were instructed to connect 1 to A, then A to 2, then 2 to B etc., without removing their pencil from the page. The time for completion was recorded and used as the primary outcome variable for each task. An additional difference measure of switching cost was calculated by subtracting Trails A time from Trails B time.

2.2.2.3. Logical Memory test

This test is part of the WMS-III, designed to assess episodic memory. Participants were read a one-paragraph story and immediately after the administration were asked to verbally recall any information from the story. In delayed recall, participants were asked to verbally recall information from the story 25–35 min after administration. The number of correctly recalled items was recorded. Participants were also given a recognition test (yes–no questions) after completion of the recall components. This widely used measure from the WMS battery is often used in diagnosis of memory problems and cognitive impairment (Larabee et al., 1985; Troster et al., 1993). Further, both DHA and PA have been associated with performance on this task in prior studies (Muldooon et al., 2010).

2.2.3. Physical activity assessment

PA levels were assessed using the Paffenbarger Physical Activity Questionnaire (PPAQ). This widely used instrument was designed to assess daily and weekly activity from self-reported levels of activities of daily living (e.g., stairs climbed) and leisure activities requiring physical exertion (e.g., sports). This instrument has high reliability (Ainsworth et al., 1993) and convergent validity with several objective measures of PA and fitness, including maximal oxygen uptake (Nowak et al., 2010), dual-energy X-ray absorptiometry (Shedd et al., 2007), and body mass index (Choo et al., 2010). The Paffenbarger questionnaire is predictive of health conditions that are related to PA, including myocardial infarction (Chomistek et al., 2011), total cholesterol and fasting blood glucose (Choo et al., 2010), bone density (Shedd et al., 2007), and inflammatory biomarkers (McFarlin et al., 2006). Weekly kilocalories were calculated from participants’ responses using criteria set by Paffenbarger (Paffenbarger, Wing, & Hyde, 1978).

2.2.4. Diet recall

Two, unannounced 24-h diet recall interviews were conducted with each participant by telephone. The interviews used the Nutrition Data System for Research, a Windows-based dietary analysis program designed for the collection and analysis of 24-h dietary recalls (NRC, 1995). The dietary interview included a 24-h dietary recall (Nutrition Coordination Center at the University of Minnesota, http://www.ncc.umn.edu/FFeskanich et al., 1989). Consumption of fiber, folate, sodium, and saturated fat were expressed per 2000 kcal and used as indicators of diet quality. Dietary information such as calories consumed per day, calories from fat, and calories from saturated fats were calculated. This information was collected on a subset of the participants ($n$ = 299) and was used in secondary regression analyses with calories from saturated fat and total fat as covariates in the model (see Section 2.3).

2.3. Statistical analyses

All variables were examined for normality, of which only kilocalories from the PA intake was significantly skewed. This measure was then normalized by a log transformation prior to analysis. In an effort to identify significant covariates, bivariate Pearson correlations were conducted between demographic variables and the independent and dependent variables of interest. While each cognitive task was selected based on its ability to measure a domain of cognition known to be sensitive to PA and DHA, each task yielded multiple measures. As a result, there were a total of eight cognitive variables of interest. To reduce the number of dependent variables and account for multiple comparisons, we first subjected the eight cognitive measures to an exploratory factor analysis with varimax rotation. This resulted in three factors with eigenvalues > 1 and corroborated by Scree test. The first factor (n-back) included the number of correct responses in the Spatial and Letter n-back tasks and accounted for 30.1% of total variance. The second factor (Trail Making) included Trails B time and Trails B–A cost and accounted for 24.10% of total variance. The third factor (Logical Memory) included Logical Memory Recall and Recognition accuracy and accounted for 21.13% of total variance (Table 1). The resulting three factors were then used as dependent variables, each accounting for one domain of cognition of interest.

Multiple regression was employed to test associations between PA and omega-3 levels on each of the three cognitive factors with age, sex, race, and years of education entered as covariates (see Section 3). A PA x omega-3 interaction term was modeled to examine whether AA:DHA ratios moderate the effects of PA on cognitive outcomes (Table 1). A PA x omega-3 interaction term was modeled to examine whether AA:DHA ratios moderate the effects of PA on cognitive outcomes (Table 1).

<table>
<thead>
<tr>
<th>Factor analysis</th>
<th>N-back factor</th>
<th>Trail Making factor</th>
<th>Logical Memory factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memory recall</td>
<td>0.934</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memory recognition</td>
<td></td>
<td></td>
<td>0.952</td>
</tr>
<tr>
<td>Trails B time</td>
<td>0.929</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trails B–A time</td>
<td>0.946</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Letter 1-back</td>
<td>0.804</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Letter 3-back</td>
<td>0.675</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spatial 1-back</td>
<td>0.830</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spatial 2-back</td>
<td>0.708</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Factor analysis conducted using all eight cognitive outcome variables. Analyses were performed with varimax rotation where eigenvalues > 1 and a threshold of 0.4 was used to determine the three factors: n-back (30.10% of total variance), Trail Making (24.10% of total variance), Logical Memory (21.13% of total variance).
Table 2
Demographics.

<table>
<thead>
<tr>
<th></th>
<th>n-3 Sample (N = 344)</th>
<th>Diet sample (N = 299)</th>
<th>Full AHAB sample (N = 1295)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Age</td>
<td>44.37</td>
<td>6.72</td>
<td>44.53</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>46.8%</td>
<td>89.0%</td>
<td>89.0%</td>
</tr>
<tr>
<td>Race (% Caucasian)</td>
<td>88.4%</td>
<td>10.35</td>
<td>10.35</td>
</tr>
<tr>
<td>Years of schooling</td>
<td>15.97</td>
<td>16.03</td>
<td>2.65</td>
</tr>
<tr>
<td>Smoking (% smokers)</td>
<td>12.2%</td>
<td>2.93</td>
<td>12.2%</td>
</tr>
<tr>
<td>Ann. household income (mean range% in range)</td>
<td>$35,000-$49,999</td>
<td>20.3%</td>
<td>$35,000-$49,999</td>
</tr>
<tr>
<td>Drinks/week</td>
<td>2.92</td>
<td>2.39</td>
<td>115.80</td>
</tr>
<tr>
<td>Kilocalories</td>
<td>2447.91</td>
<td>1727.26</td>
<td>2408.07</td>
</tr>
<tr>
<td>AA</td>
<td>8.76</td>
<td>1.94</td>
<td>8.50</td>
</tr>
<tr>
<td>DHA</td>
<td>1.74</td>
<td>0.86</td>
<td>1.62</td>
</tr>
<tr>
<td>EPA</td>
<td>0.50</td>
<td>0.36</td>
<td>0.050</td>
</tr>
<tr>
<td>AA:DHA</td>
<td>5.99</td>
<td>2.42</td>
<td>6.13</td>
</tr>
<tr>
<td>Calories from fat</td>
<td></td>
<td></td>
<td>33.86</td>
</tr>
<tr>
<td>Calories from saturated fat</td>
<td></td>
<td></td>
<td>11.60</td>
</tr>
</tbody>
</table>

3. Results

3.1. Demographic analyses

We found no significant association between AA:DHA and sex or PA. More years of education was associated with lower AA:DHA ratios ($r = -0.166, p = 0.002$) and greater amounts of PA ($r = 0.136, p = 0.012$). PA was also related to race such that whites displayed higher amounts of PA than non-whites ($t(342) = 3.482, p = 0.001$). Age was not correlated with either AA:DHA or PA (both $p > 0.05$). No other associations reached significance ($p > 0.05$) (see Table 3).

3.2. Main effects of PA and AA:DHA on cognitive performance

Consistent with anticipated results, there was a significant association between PA and the N-Back factor ($\beta = 0.178, t = 2.543, p = 0.01$) such that greater amounts of PA were associated with better performance after controlling for age, sex, race, and years of education. In secondary analyses of the tasks composing the N-back factor, we found a significant main effect of PA on the Letter 3-Back ($\beta = 0.149, p = 0.007$), Spatial 1-Back ($\beta = 0.163, p = 0.003$), and Spatial 2-back ($\beta = 0.116, p = 0.032$) tasks such that greater amounts of PA were associated with better performance. There were no significant associations between PA and the Trail Making factor ($\beta = -0.009, t = -1.687, p = 0.092$) or Logical Memory factor ($\beta = 0.055, t = 1.103, p = 0.305$).

Inconsistent with our predictions, there were no significant associations between serum AA:DHA ratio levels and any of the three factors examined: N-Back ($\beta = 0.001, t = 0.18, p = 0.986$), Trail Making ($\beta = 0.076, t = 1.385, p = 0.167$), or Logical Memory ($\beta = -0.028, t = -0.531, p = 0.596$) after controlling for variance associated with age, sex, race, and years of education. Similarly, no associations were found between cognitive performance and each PUFA individually. That is, there were no significant main effects of AA on any factor (all $p > 0.30$), nor was there a significant main effect of DHA for the N-Back factor ($\beta = 0.015, p = 0.776$), Trail Making factor ($\beta = -0.093, p = 0.089$), or the Logical Memory factor ($\beta = 0.021, p = 0.697$).

3.3. AA:DHA moderates effects of PA on cognitive performance

In support of our hypothesis, there was a significant interaction between serum AA:DHA ratio and PA on the N-Back factor ($\beta = 1.222, t = 2.145, p = 0.033$) and the Trail Making factor ($\beta = -1.478, t = 1.852, p = 0.065$).
N-Back indicates greater accuracy and greater performance. Between kilocalories and AA:DHA was observed. Note: Higher values for Trail Making indicates longer time to completion and poorer performance, while higher values for such that a value of 0 denotes the mean value of the sample. Significant interactions were found for N-Back and Trail Making factors, while no significant relationship between kilocalories and AA:DHA was observed. Note: Higher values for Trail Making indicates longer time to completion and poorer performance, while higher values for N-Back indicates greater accuracy and greater performance. In contrast, the interaction was not significant for the easier working memory conditions, the Letter 1-back (β = −0.205, t = −2.057, p = 0.010). In contrast, there was no significant interaction between PA and AA:DHA for the Logical Memory factor (β = 0.200, t = 0.354, p = 0.724). Decomposing these significant interactions revealed that individuals with higher AA:DHA ratios and lower amounts of PA performed more poorly than their peers with lower AA:DHA ratios or higher amounts of PA (see Fig. 1).

In secondary analyses, we found that the more challenging working memory conditions, the Letter 3-Back (β = 1.562, t = 2.720, p = 0.007) and Spatial 2-Back tasks (β = 1.503, t = 2.685, p = 0.008), were driving the N-back factor results such that lower AA:DHA ratios offset the association between lower PA and poorer performance. However, the combination of higher AA:DHA ratios (higher proportion of AA to DHA) with lower PA was associated with markedly decreased performance. In contrast, the interaction was not significant for the easier working memory conditions, the Letter 1-back (β = 1.011, t = 1.762, p = 0.079) and Spatial 1-back (β = 0.760, t = 1.330, p = 0.184) (see Fig. 2B).

Similarly, when examining the Trail Making Factor in secondary analyses, we found that both Trails B (β = −1.615, t = −2.889, p = 0.004) and Trails B-A (β = −1.596, t = −2.808, p = 0.005), displayed the same moderating relationship as the N-back (Fig. 2A) such that lower AA:DHA ratios offset the association between lower PA and poorer performance. In analyses of individual fatty acids, we found that AA did not moderate the effect of PA on the N-Back factor (β = −0.205, t = −2.053, p = 0.725), Trail Making factor (β = −0.359, t = −0.963, p = 0.336), or Logical Memory factor (β = −0.027, t = −0.047, p = 0.963). In contrast, DHA significantly interacted with PA on the N-Back factor (β = −1.390, t = −2.467, p = 0.014). Decomposing this effect revealed significant interactions between DHA and PA for the Letter 3-Back (β = −1.169, t = −2.044, p = 0.042), Spatial 1-Back (β = −1.317, t = −2.336, p = 0.020), and Spatial 2-Back (β = −1.417, t = −2.554, p = 0.011) tasks. Similar to the factor scores, decomposing these interactions revealed that higher DHA levels offset the association between lower PA and poorer performance. There were no significant interactions between DHA and PA with the Trail Making factor (β = 0.795, t = 1.391, p = 0.165) or the Logical Memory Factor (β = 0.100, t = 0.178, p = 0.859) – see Table 4.

After adding calories from fat and calories from saturated fat into the regression model as covariates for a subset of the sample (n = 299), the results were unchanged (see Table 5 for regression results). Here too, the secondary analyses revealed that lower AA: DHA ratios offset the association between less PA and worse performance on the Trail Making and N-back tasks.

4. Discussion

We predicted that omega-3 PUFAs, as quantified by serum AA: DHA ratio levels, would moderate an association between PA and cognitive performance. The first hypothesis, based on animal research (Chytrova et al., 2010), was that a lower ratio of AA: DHA would magnify the positive association between higher amounts of PA and cognitive performance. We failed to find support for this hypothesis. That is, there was no evidence for an additive or multiplicative benefit of greater amounts of PA in combination with lower AA:DHA ratios on cognitive performance. Our second hypothesis, based on behavioral evidence from rodent studies (Chytrova et al., 2010), was that a high AA:DHA ratio would exacerbate the detrimental effects of physical inactivity on cognitive...
to individuals engaging in higher amounts of PA or with a low AA:DHA ratio. In summary, our results suggest that the undesirable effects of a physically inactive lifestyle on cognitive performance might be partially mitigated by greater intake of omega-3 fatty acids.

As previously discussed, PA increases cell proliferation and synaptogenesis in the hippocampus (van Praag, Kempermann, & Gage, 1999), increases expression of BDNF (Stranahan et al., 2009; Vivar, Potter, & van Praag, 2012), alters dopaminergic circuitry in the cortex (Fisher et al., 2004; Knab et al., 2009; MacRae et al., 1987; Petzinger et al., 2007) and influences the expression and re-uptake of serotonin (Dey, Singh, & Dey, 1992; Speelman et al., 2011; Wipfl et al., 2011). However, PA may also influence inflammatory pathways or influence brain function by improving vascular pathways. Importantly, DHA has also been found to influence BDNF, dopamine, serotonin, vascular reactivity, and anti-inflammatory pathways (Cardoso et al., 2013; Pestrin et al., 2010; Tanaka et al., 2012). While it is not clear which molecular system(s) is contributing to the moderating effect of omega-3 on the association between PA and cognitive function, the parallels between the molecular pathways are hard to ignore.

DHA is critical for maintaining cell membrane structure, fluidity and ion permeability (Kidd 2007; Wu et al., 2008) and is only synthesized in small amounts in humans, requiring it to be consumed to maintain recommended levels. Several studies have suggested that DHA might play an important role in cognitive function (Kidd 2007; Matchyński et al., 2013; Muldoon et al., 2010; Tanaka et al., 2012; Wu, Ying, & Gomez-Pinilla, 2011) because it is a primary fatty acid in the structure of the neuron membrane (Wu et al., 2011), influences inflammation, and is thought to be involved in cardiovascular and metabolic processes, all of which could influence cognitive performance (Gomez-Pinilla & Tyagi, 2013). Cross-sectional studies have reported results consistent with this reasoning, yet several interventions of omega-3 supplementation have failed to find strong evidence in favor of omega-3 intake as a treatment or prevention for cognitive decline (e.g., Alzheimer's disease) (Mazereeuw et al., 2012; Sydenham, Dangour, & Lim, 2012). In response to the null findings reported from randomized trials, there has been speculation that omega-3 interventions beginning earlier in life, administered for longer durations, at higher doses, or more careful screening of habitual dietary patterns, might provide a more revealing pattern. Our results complement this line of reasoning and go further to suggest that omega-3 levels should be assessed carefully alongside other modifiable factors (e.g., PA) when examining cognitive performance. Indeed, interactions between omega-3 and PA could explain some of the heterogeneous results linking DHA or DHA supplementation to cognitive performance.

Importantly, our results remained significant even when controlling for potentially confounding factors including age, sex, race, and years of education. Further, when controlling for fat consumption in a subset of the sample, the interaction between PA and AA:DHA remained significant. In addition, AA did not by itself moderate the association between PA and any of the cognitive factors or their components, while DHA by itself was a significant moderator of PA, although only for the N-Back factor. These results suggest that DHA was the primary component in the AA:DHA interaction with PA on the n-back task. It is intriguing to speculate why DHA by itself did not significantly interact with PA for the Trails factor while the AA:DHA did. In line with other studies, this effect suggests that the competition between AA and DHA, captured by the ratio, but not by the individual PUFAs, is critical when assessing its relation to cognitive performance. Moreover, this result suggests that it is primarily the AA:DHA ratio that is interacting with PA to influence executive function as measured by the Trail Making test.
There were several limitations to this study. First, given the cross-sectional design, we cannot draw causal conclusions about PA and omega-3 with respect to cognitive function. Hence, these analyses cannot ascertain whether poorer cognitive function leads to lower intake of DHA or less PA or whether lower DHA and PA lead to poorer cognitive function. To make causal conclusions, an intervention would need to be conducted in which supplementation of omega-3 and initiation of PA were randomized and systematically administered. Second, the Paffenbarger PA questionnaire is self-report, prone to subject bias (Voorrips, Revelli, Dongelmans, Deurenberg, & Van Staveren, 1991) and may not reflect PA accurately. Yet, despite this limitation we were able to detect significant main effects of PA on n-back performance. Nonetheless, future studies could utilize actigraphy and other objective measures of PA and fitness to obtain more accurate assessments. Third, PUFA serum levels only reflect measures at the time of blood sampling. It is possible that the amount of PUFAs in brain tissue is not re-accumulate over time.

In summary, the present study revealed that AA:DHA levels moderate the association between PA and working memory and task-switching, such that high levels of DHA relative to AA mitigate the effects of lower levels of PA on performance. We failed to find additive effects of high levels of PA and high levels of DHA relative to AA on cognitive function. This study provides compelling initial evidence that dietary factors influence the association between PA and cognitive performance. Additionally, the results from this study have the potential for significant public health implications on recommended dietary and PA regimens.

Acknowledgments

The authors would like to acknowledge Angus McDonald for his contribution to the development of the N-Back task. Additional thanks extend to the AHAB group for data collection and organization. This project was supported by US NIH Grants P01 40962 and T32 HL007560. KIE was supported by NIH grant R01 DK09172.

References


Table 5

<table>
<thead>
<tr>
<th>Table 5</th>
<th>AA:DHA × physical activity regression results.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Full sample (N = 344)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>β</strong></td>
</tr>
<tr>
<td>N-back factor</td>
<td></td>
</tr>
<tr>
<td>Letter 1-back</td>
<td>1.222*</td>
</tr>
<tr>
<td>Letter 3-back</td>
<td>1.011</td>
</tr>
<tr>
<td>Spatial 1-back</td>
<td>1.562**</td>
</tr>
<tr>
<td>Spatial 2-back</td>
<td>0.760</td>
</tr>
<tr>
<td>Trail Making factor</td>
<td>1.503**</td>
</tr>
<tr>
<td>Trails B time</td>
<td>−1.478**</td>
</tr>
<tr>
<td>Trails B – A time</td>
<td>−1.615**</td>
</tr>
<tr>
<td>Logical Memory</td>
<td>−1.596**</td>
</tr>
<tr>
<td>Memory recall</td>
<td>0.200</td>
</tr>
<tr>
<td>Memory recognition</td>
<td>0.516</td>
</tr>
<tr>
<td></td>
<td>0.810</td>
</tr>
</tbody>
</table>

Omege-3 × physical activity regression results: moderation analyses included age, sex, education, and race as covariates. Total calories from saturated fat from diet and total calories from fat were included in the moderation analyses as covariates in the sub-sample with available dietary data.

* p > 0.05.

** p > 0.01.


